Navigation Links
Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
Date:9/13/2010

strong results from both Preclinical eValuation and Personalized Oncology.  In addition, with the hiring of our Preclinical Sales Director in August 2010, we are positioned to reach out to more pharmaceutical companies that can utilize our Preclinical eValuation platform."

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs.  The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor.  The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials.  As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate.  The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to Companies for evaluation of oncology drugs and drug candidates in models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized tr
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
2. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
3. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
4. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
5. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
6. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
7. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
8. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
9. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
10. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
11. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... LAWRENCEVILLE, N.J. , May 28, 2015 ... announced that it has received commitments from two institutional ... million of the Company,s common stock in an at-the-market ... warrants to purchase common stock. The Company ... pursuant to which the Company agreed to sell an ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Fertility Centers of New England is proud to announce ... a new and expanded role as Medical Director. In ... and quality assurance for the practice. , “We are ... experienced reproductive endocrinologists,” said Fertility Centers of New England ... and compassionate, individualized care have helped set FCNE apart ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... Inc.,(NASDAQ: VSGN ; TSX:VAS), today announced that it ... its cash burn rate and focus its,efforts on ... most,likely to provide long-term shareholder value. This plan ... series of drugs while the,Company seeks alternatives to ...
... April 14 Metabolex, Inc., a,biopharmaceutical company ... new medicines for the treatment of metabolic ... joined the company as chief,financial officer. Mr. ... to Metabolex, including expertise in business,development, treasury ...
... form basis of blood-based ColonSentry(TM) test -, ... GEN),a company focused on developing blood-based biomarker tests ... management, today reported,positive performance results from a large ... assessment of a patient,s current risk for,colorectal cancer. ...
Cached Biology Technology:Vasogen Announces Implementation of Strategic Restructuring Plan 2Vasogen Announces Implementation of Strategic Restructuring Plan 3Vasogen Announces Implementation of Strategic Restructuring Plan 4Vasogen Announces Implementation of Strategic Restructuring Plan 5Metabolex Appoints Donald Hill as Chief Financial Officer 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/21/2015)... , May 21, 2015 The ... potential of music for health, today announced a collaborative ... . The partnership will center on collaboration on original ... a first step in the collaboration, The Sync Project ... on "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... to adapt to moderate climate warming, improving their chance of ... large reductions in carbon dioxide emissions, according to a study ... its academic partners. Results further suggest corals have already adapted ... modeling work suggested that coral reefs would be gone by ...
... Recent years have seen significant outbreaks of listeriosis on ... usually be treated successfully, it is occasionally fatal, most ... when treatment is effective, the symptoms are anything but ... diarrhoea and other gastrointestinal symptoms. The old adage is ...
... is a lead partner in a new 6 million ... treat Cystic Fibrosis. Affecting more than 10,000 people ... the most common life-threatening inherited diseases. Symptoms include repeated ... The new global programme, known as CF Matters, aims ...
Cached Biology News:New study suggests coral reefs may be able to adapt to moderate climate change 2New study suggests coral reefs may be able to adapt to moderate climate change 3Passing the Gac 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
... GenBank Accession Number : ... (C-QSQENQDTRPKVKAKK), corresponding to amino acids ... Formulation: antiserum in 0.05% sodium ... Assurance: routinely evaluated by immunoblot ...
Request Info...
...
Biology Products: